Search Results for "Opana Electronic Prescribe"
Original Source: Opana [Endo Pharmaceuticals Inc.]
These highlights do not include all the information needed to use OPANA ER safely and effectively. See full prescribing information for OPANA ER. OPANA ER (oxymorphone hydrochloride) Extended-Release tablets, CII Ini
Matching Channels
The US FDA is the Food and Drug Administration . FDA is responsible for: Protecting the public health by assuring that foods are safe, wholesome, sanitary and properly labeled; human...
Health IT Information Technology
Why Health IT? Health information technology (Health IT) makes it possible for health care providers to better manage patient care through secure use and sharing of health information - e...
Vasodilation refers to the widening of blood vessels resulting from relaxation of smooth muscle cells within the vessel walls, particularly in the large arteries, smaller arterioles and large veins....
For optimal treatment in cancerology, clinicians need specific, precise, sensitive methods to quantify treatment response, monitor residual disease and detect early recurrence in patients. Residual...
The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...
Matching News
FDA Rejects Endo Petition To Protect Its Opana Painkiller
The FDA rejected a citizen petition filed by Endo Pharmaceuticals which hoped to protect its Opana painkiller franchise by convincing the agency to require generics to be similarly abuse deterrent as...
Endo submits Citizen Petitions calling for future generics of OPANA ER to be held to the same crush-resistant development standards CHADDS FORD, Pa., September 06, 2012, 2012 /PRNewswire/ -- Endo Phar...
(MedPage Today) -- The original formulation of extended-release oxymorphone (Opana ER) that lacked abuse-resistant mechanisms was not pulled from the market for safety reasons, and therefore generics...
Coming In Tuesday's "The Pink Sheet" DAILY - Endo Seeks To Block Generic Versions Of Opana ER
Endo files citizen petition opposing approval of ANDAs referencing Opana ER - FDA panel to review technologies for finding adventitious agents in vaccines
Endo Health Solutions - Opana Story De-Emphasized, Buyout Re-Emphasized
ByPropThink: By Jake King A price target reduction from RBC Capital Markets took $1.06 (or 3.4%) out of Endo Health Solutions (ENDP) Thursday, noting risks to the company's pain product, Opana ER. A...
FDA Rejects Endo’s Deadline On Opana ER Petition; Impax Product May Become New RLD
Endo files suit against FDA seeking preliminary injunction to require FDA to say whether Endo’s withdrawal of non-crush resistant Opana ER was for safety reasons; FDA contends it has until May 10, 2...
Abuse of 'New' Opana Linked to Blood Disorder
(MedPage Today) -- Drug users who inject the new "abuse-deterrent" version of Opana ER (oxymorphone) may be at risk of developing a serious blood disease, according to Tennessee health officials.
Impax begins patent challenge over Opana ER generic version
America's Impax Laboratories has begun the challenging process against the suit filed by two companies for patent infringement over a generic version of Opana® ER (oxymorphone hydrochloride extended-...
Matching PubMed Articles
A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia.
BACKGROUND: There is an impression of poor management of pregnancy sickness in Australia, specifically an apparent total reliance on metoclopramide, as a first-line choice. AIMS: To determine what man...
BACKGROUND: The pharmaceutical industry spends billions of dollars annually to encourage clinicians to prescribe their medications. Small studies have demonstrated that one of the marketing strategies...
Why doctors prescribe opioids to known opioid abusers.
